Apimeds Pharmaceuticals US (APUS) Other Non-Current Liabilities (2023 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Other Non-Current Liabilities came in at $1.6 million in Q4 2025, up 827.06% on a QoQ basis from $174413.0 in Q2 2025.
Apimeds Pharmaceuticals US (APUS) Other Non-Current Liabilities (2023 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 2 years of Other Non-Current Liabilities data on file, last reported at $1.6 million in Q4 2025.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.6 million (changed N/A YoY) and the FY2025 annual result came in at $1.6 million, changed N/A from the prior year.
- Other Non-Current Liabilities rose to $1.6 million in Q4 2025, from $174413.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $1.6 million in Q4 2025 to a low of $68878.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - |
| 10 | Apimeds Pharmaceuticals US | 7.12 Mn | 7.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.62 Mn |
| Jun 30, 2025 | 174,413.00 |
| Dec 31, 2023 | 68,878.00 |